Currently Viewing:
AMCP 2017
Dr Jennifer Graff on How Payers Make Decisions
August 01, 2017
Laura Topor Discusses Challenges of e-Prescribing Specialty Medications
July 11, 2017
Dr Jacqueline Glover: Financial Knowledge Is Part of Informed Consent
July 10, 2017
Laura Topor Explains the Value of Real-Time Benefit Transactions
June 27, 2017
Dr Jacqueline Glover: Clinicians' Obligations of Justice Regarding Costs of Care
June 24, 2017
Dr Lou Garrison Discusses Challenges of Working With Real-World Data
June 16, 2017
Dr Neil Minkoff Explains How 340B Impacts Pharmacies and Payers Differently
June 15, 2017
Dr Matthew Pickering on Working With Health Plans on Measure Implementation
June 09, 2017
Laura Topor: Clearing Up Misconceptions About e-Prescribing
June 07, 2017
Dr Jacqueline Glover Discusses the Complicated Balance of Ethics in Drug Trials
June 05, 2017
Dr Richard J. Willke Discusses Challenges of Working With Real-World Data
June 02, 2017
Susan A. Cantrell Explains the Necessity of Pre- and Post-Approval Communications
May 31, 2017
Dr Neil Minkoff Discusses Evolution and Consequences of 340B Programs
May 30, 2017
Dr Doug Hillblom Discusses Legislative Pushes Toward e-Prescribing
May 25, 2017
Dr Matthew Pickering Describes Challenges of New Measure Implementation
May 24, 2017
Dr Aimee Tharaldson Discusses the Orphan Drug Approval Trend
May 22, 2017
Dr Gail Bridges on the Importance of Real-World Results Matching Clinical Trial Outcomes
May 21, 2017
Currently Reading
Dr Liz Zhou Discusses Real-World Implications of Toujeo Switching Trial
May 19, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Liz Zhou Discusses Real-World Implications of Toujeo Switching Trial

Findings from real-world studies will help clinicians and other health stakeholders better understand the use of Toujeo compared with Lantus, particularly regarding treatment dosage patterns, for patients with type 2 diabetes, according to Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs.


Findings from real-world studies will help clinicians and other health stakeholders better understand the use of Toujeo compared with Lantus, particularly regarding treatment dosage patterns, for patients with type 2 diabetes, according to Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs.

Transcript (slightly modified)

What did you learn from clinical trials on comparing real-world results of basal insulin dose changes that will inform future studies on glargine?

There actually have been a lot of questions about Toujeo dosing from clinicians and the payer side, for instance, does Toujeo require higher dosing? In this study, what we see is that for patients who are the matched cohort who are persistent in their treatment in the 6 months follow up, an up-titration of 7 to 9% of basal insulin was observed. Regardless of whether those are patients who switched from Lantus to Toujeo, or they continued on Lantus, which actually proves or confirms that there’s a need for titration, an up-titration, especially for patients with type 2 diabetes that experience disease progression or clinical inertia.

In addition, we also see that the percent those change for Toujeo and the percent those change for Lantus are comparable, and we see similar A1c in the baseline and the follow-up. I think that’s very informing, that’s why we think this study is very timely for the healthcare decision makers to better understand the usage of Toujeo compared to Lantus in the real-world setting, especially looking at treatment pattern and dosing.

What is a key takeaway from the study?

The research really looked into insulin dosing, and we wanted to look into claims data more, and beyond dosing, we wanted to look further into the clinical outcomes for the patients who stayed on Lantus or switched to Toujeo. Hoping to provide additional evidence beyond the Toujeo EDITION programs, looking into different types of outcomes.

Dosing is more of a treatment pattern type of outcome; clinical outcomes, persistence, and in the future healthcare utilization and costs are something that we want to look further into. I think this first study on claims is giving us a very good idea of the direction we’re going.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!